

Original Research Article

High prevalence of isolated hepatitis B core antibody among adults in Oyo State, Nigeria: the need for review of diagnostic and vaccination guidelines

ABSTRACT

Background: Ten years of neonatal immunization with hepatitis B vaccine has not had any significant effect on the prevalence of the disease in Nigeria.

Aim: To investigate hepatitis B virus (HBV) markers as potential risk factors for viral transmission.

Study design: A pilot prevalence study.

Place and Duration of Study: Community centers in Ibadan and Ogbomosho, between July 2014 and September 2014.

Methodology: One hundred and ninety-two apparently healthy volunteers (61 men, 131 women: age range 11-88 years) were investigated for HBV serological/immunological markers using enzyme linked immunoassays with 99 - 99.7% and 98.4 - 100% for specificity and sensitivity respectively (Diagnostic Automation/Cortez Diagnostics, Inc., Calabasas, CA, USA). Also data were processed with the statistical package for the social sciences version 20.0 (SPSS Inc., USA).

Results: A prevalence of 22.9%, 14.6%, 19.3%, 90%, 53.6%, 6.8% and 22.9% was obtained for HBsAg, HBsAb, HBcAb-IgM, HBcAb-Total, isolated HBcAb, HBeAg, and HBeAb, respectively. Analysis of the lifetime exposure of 90% among participants showed that 44 and 103 have markers for present (HBsAg) and past (isolated HBcAb) infections respectively, while 26 recovered with evidence of surface antigen neutralizing antibodies (HBsAb) in their serum. Seropositivity for HBsAg was highest among males and the 21-30 years old, while the female gender and persons **aged between 30 and 40 years** accounted for the largest percentage of isolated HBcAb carriers. Although history of exposure to risk factors like scarification, tattooing, injection from **quacks**, surgery, blood transfusion, sharing of sharp instrument/tools and injection drug use was common among participants, only 15.6% took hepatitis B immunization. On the overall, the risk of HBV infection was **significantly associated with scarification and sharing of sharp instruments and tools.**

Conclusion: The study highlights potential risk associated with the current diagnostic guideline for hepatitis B status and advocates the need for immunization among susceptible

unvaccinated population.

Keywords: Hepatitis B virus, Isolated HBcAb, Adult Population, High Prevalence, Nigeria.

1. INTRODUCTION

Hepatitis B is a potentially life-threatening infection of the liver, ranked by the World Health Organization as one of the most common and serious infectious disease worldwide [1]. Presently three quarters of the world's population live in highly endemic areas, while about 2 billion are estimated to be infected [1]. Therefore the global disease burden of hepatitis B is substantial. Every year, there are over 4 million acute cases and about 25% of carriers, while 1 million people die from chronic active hepatitis, cirrhosis or primary liver cancer [1]. Hepatitis B is highly endemic in developing countries of Southern Asia and Tropical Africa, where at least 8% of the populations are chronic carriers and 70-90% becomes infected before the age of 40, showing past or present serological evidence of hepatitis B virus (HBV) infection [1]. Although most infections occur in children with little evidence of acute disease related to HB, the rates of chronic liver disease and liver cancers in adults are high [2].

The virus is transmitted majorly by exposure to infectious body fluids and sexual intercourse, while risk factors include medical/dental/surgical procedures, living with an infected person, multiple sex partners, reusing of needles and syringes, tattooing, risky sexual activities, and sharps contaminated with infected blood as well as working in healthcare facilities [3]. Hepatitis B is a vaccine preventable disease, and about 85-90% of HBV-associated death can be prevented, when given before or shortly after exposure. However, in spite of the availability of safe and effective vaccine for an upward of 20 years, worldwide infection persists [1]. Nigeria has adopted the universal neonatal vaccination through the expanded programme on immunization (EPI) and had utilized a monovalent hepatitis B vaccine since 2004. However in 2012, a pentavalent containing hepatitis B vaccine was introduced to commence at 6 weeks after the initial monovalent dose given at birth. Despite this continuous immunization exercise, the prevalence of HBV infection among Nigerians has remained high. Hence it becomes important to assess the population for viral factors with potential for the spread of the disease.

Immunity to HBV develops only in persons who are vaccinated or exposed to transient infection. Therefore, the prevalence of hepatitis B surface antigen (HBsAg) alone may be an underestimation of the current hepatitis B status in any population. Although most publications from Nigeria investigated the surface antigen prevalence [4-7]; data from other parts of the world have shown that this is not sufficient to predict latent infections. The recovery of HBV for many years in the blood of infected persons following clinical recovery and the induction of HBV-specific antibodies and cytotoxic T lymphocytes corroborated this fact [8]. Also HBV transmissions have been reported from surface antigen negative but hepatitis B core antibody (HBcAb) positive healthy individuals under various circumstances [9-12]. Therefore, HBsAg seronegativity does not exclude the existence of HBV DNA in the blood and liver tissue of individuals with previous exposure to the virus. In this study, we have investigated a cohort of apparently healthy individuals for HBV markers. This is necessary to generate data to propose recommendations for limiting the spread and reducing the prevalence of the disease in the nearest future.

2. MATERIAL AND METHODS

2.1. Study Population

Public educational programs were organized bi-monthly at the community centers to give information on hepatitis B disease, risk factors, prevention, and control to participants. The study was conducted for 3 months (July - September 2014) in two cities (Ogbomosho and Ibadan) in Oyo State, Nigeria. However only consenting participants (older than 10 years) who were apparently healthy, with unknown hepatitis B status and have not had hepatitis B related symptom in the past were recruited for this study. Hence individuals who presently had ill health, knew their hepatitis B status and have had hepatitis B related symptoms in the past were excluded to reduce sampling bias. The apparent health status of participants was evaluated from normal vital signs measurement and the absence of a medical complaint.

2.1.1. Data collection

Relevant information describing the demography, as well as past and present behavioural risks and exposure was obtained from recruited individuals. These include age, sex, occupation, marital status, scarification, transfusion, surgery, tattooing, indiscriminate injection from non-professional healthcare practitioners, drug abuse, multiple sex partners, sharing of sharp objects, and hepatitis B immunization status.

2.1.2. Sample collection

Three millilitres (3 mL) of venous blood specimen was collected from each participant. Samples were kept in upright position at room temperature for 45 minutes to allow clotting. Samples were spun for 15 minutes at 1,500 rpm at 4°C. The supernatant (sera) were aliquoted in 0.5 mL labelled cryovials and stored at -40°C until used.

2.2. Sample Analysis

Assessment of recruited persons for HBV markers was done using some sets of antigen-antibody systems. These are the: the surface antigen-antibody system (HBsAg, HBsAb), envelope antigen-antibody system (HBeAg, HBeAb), core antibody system (HBcAb-IgM, HBcAb-Total). The ELISA kits (HBsAg, HBsAb, HBcAb, HBcAb IgM, HBeAg, HBeAb) were used according to the manufacturer's instructions (Diagnostic Automation/Cortez Diagnostic Inc., Calabasas, California, USA).

2.2.1. Detection of HBsAg and HBeAg

The analysis uses an antibody sandwich ELISA technique in which polystyrene microwell plates were pre-coated with monoclonal antibodies specific to HBsAg. Fifty microliters (50 µl) of test sera were added to plates together with 50 µl of a second antibody conjugated to the enzyme horse radish peroxidase (HRP-conjugate) directed against a different epitope of HBsAg. The incubation at 37°C for 60 minutes allowed the formation of a specific immunocomplex which was captured on a solid phase. After washing 5 times with diluted wash buffer, chromogen solution containing tetramethyl benzidine (50 µl) and urea peroxide (50 µl) were added to the wells and was followed by incubation at 37°C for 15mins in the dark. The enzymatic reaction between the chromogen solutions and the HRP-conjugate produces blue coloured product in HBsAg positive wells. Finally intense yellow colour developed in positive wells following the addition of 50 µl stop solution. Absorbances were read with a dual filter reader at 450nm/630nm, and specimen giving an absorbance equal to or greater than the cut-off value was considered reactive.

2.2.2. Detection of HBsAb

The kit employed an antigen sandwich ELISA technique with recombinant HBsAg pre-coated on polystyrene microwells. Test sera (50 µl) and the horse radish peroxidase-conjugate (50

μl) were then added to labelled wells and plates incubated at 37°C for 60mins. The presence of anti-HBs initiated the binding of pre-coated and conjugated antigens to the two variable domains of the antibody, to form a specific immunocomplex captured on the solid phase during incubation. Following the removal of unbound HRP-conjugates by washing, 100 μl of chromogen solutions were added to the wells. The chromogens were hydrolysed by the bound HRP-conjugate during incubation for 15mins at 37°C in the dark to a blue coloured product which turned yellow after stopping the reaction with 50 μl sulphuric acid. Colour intensity was read at 450nm/630nm and specimens with values greater than or equal to the cut-off are considered reactive.

2.2.3. Detection of IgM HBcAb

The principle of the IgM HBcAb ELISA was based on two-step incubation, solid phase antibody capture ELISA. To polystyrene microwells pre-coated with antibodies intended for human immunoglobulin M proteins were added 100 μl of test sera and were incubated at 37°C for 30 min. This was followed by washing to remove IgG-class antibodies and other sample components. The specific anti-HBc IgM captured on the solid phase was then identified by the addition of purified HBcAg which is marked with anti-HBc monoclonal antibody conjugated to horseradish peroxidase (HRP). At the time of second incubation (37°C for 30 min), the HRP-conjugated antigens reacted with anti-HBc IgM antibodies. Then, 100 μl of chromogen solutions were added after washing, and the content of the well reactive to HBcAb IgM turned from blue to yellow by the addition of a stop solution. Plates were read with a dual filter at 450nm/630nm and values greater than or equal to the cut-off were positive.

2.2.4. Detection of total HBcAb and HBeAb

The ELISA test used is based on the solid phase, competitive assay with one step incubation. Test sera were added to plates and incubated at 37°C for 60 min. During incubation, the antibody present in the test sera competed with monoclonal antibodies conjugated to horseradish peroxidase for a fixed amount of purified antigen pre-coated in the wells. Plates were washed, followed by the addition of 100 μl chromogens which turned blue when the colourless chromogens were hydrolysed by the bound HRP-conjugate. Reaction was stopped with 50 μl of the stop solution to give a yellow colouration. Absorbance's were read with a dual filter instrument, and values less than or equal to the cut-off were considered positive.

2.3. Data Analysis

The data collected and ELISA results on HBV markers were processed with the statistical package for the social sciences Version 20.0 (SPSS Inc., USA). A significant association between outcome and predictor variables was calculated using multivariate logistic regression at 95% confidence interval and $P < 0.05$ was considered significant.

3. RESULTS

3.1. Demographic characteristics of participants

During the 3-month study period from July to September 2014, 192 consented volunteers were recruited for this pilot study. Participants included 31.8% (61) males and 68.2% (131) females. The larger number of women in attendance at the educational programs was responsible for the inclusion of more women in the study. Also 125 persons (65.1%) were married, while 45 (23.4%) had more than one sex partner (Table 1). Recruited individuals were evenly spread through the 21-30, 31-40 and 41-50 age groups with 49, 56 and 44 individuals respectively, while the >11-20 and >50 years had 22 and 21.

The analysis of past exposure to risk factors showed that 51% and 16.1% had scarification and tattooing on their bodies, while 17.2% and 16.7% had undergone surgical procedure

and took blood transfusion respectively (Table 1). Although sharing of sharp objects like knives, razor, etc. was a common practice and reported by 140 (72.9%) participants, only 65 (33.9%) took injection from quacks, while 8 participants (4.2%) reported administration of unknown injectable provided by friends a few times. On the overall, only 30 (15.6%) participants took preventive HB vaccine.

Table1: Demography and exposure to risk factors among apparently healthy participants in Ibadan and Ogbomosho, Oyo State, Nigeria

Variable	Total participants	Percentage
Demography		
Age categories		
>11-20	22	11.5
21-30	49	25.5
31-40	56	29.2
41-50	44	22.9
>50	21	10.9
Sex		
Female	131	68.2
Male	61	31.8
Risk factors		
Scarification	98	51.0
Blood transfusion	32	16.7
Tattooing	31	16.1
Surgery	33	17.2
Injection from quacks	65	33.9
Multiple sex partner	45	23.4
Injection drug use	8	4.2
Sharing of sharp Instruments/tools	140	72.9

3.2. Detection of HBV markers
A total of 44 (22.9%) participants were positive for HBsAg. Thirty seven of them had acute (HBcAbIgM+) and seven were chronic infection. The prevalence for HBSAg was higher among males (54.5%) while the 21-30 years category accounted for 36.4% of infected

persons (Table 2). However HBsAg detection rate was lowest at the two extreme age categories representing 11.4% and 4.5% for 11-20 and >50 age groups respectively. Core antibody (HBcAbTotal) was found in 173 (90%) with 103 (53.6 %) representing isolated anti-HBc. The protective immunity to HBV (anti-HBs) was present only in 28 (14.6%) individuals; while a total of 17 (9%) had no serologic marker for HBV. Further investigation of hepatitis B status showed that 13 of the HBsAg positive cases were highly infectious; being HBeAg reactive, while 27 had seroconverted with anti-HBe in their blood. In addition, 10 participants with isolated anti-HBc and 7 with HBsAb were reactive for anti-HBe (Table 3).

Table 2: Distribution of Hepatitis B markers among apparently healthy participants in Ibadan and Ogbomosho, Oyo State, Nigeria

Variable	Total	HBsAg- HBcAb+ HBsAb+	HBsAg- HBcAb+ HBsAb-	HBsAg- HBcAb- HBsAb+	HBsAg+ HBcAb- HBsAb-	HBsAg+ HBcAb+ HBsAb-	HBsAg- HBcAb- HBsAb-
Number	192	26	103	2	1	43	17
studied	(100%)	(13.5%)	(53.6%)	(1.04%)	(0.52%)	(22.4%)	(9%)
Sex							
Female	131	22 (84.6%)	76 (73.8%)	1 (50%)	1 (100%)	19 (44.2%)	12 (70.6%)
	(68.2%)						
Male	61	4 (15.4%)	27 (26.2%)	1 (50%)		24 (55.8%)	5 (29.4%)
	(31.8%)						
Age groups (years)							
> 11-20	22	1 (3.8%)	11 (10.7%)	1 (50%)		5 (11.6%)	4 (23.5%)
	(11.5%)						
21-30	49	4 (15.4%)	24 (23.3%)			16 (37.2%)	5 (29.4%)
	(25.5%)						

31-40	56 (29.2%)	11 (42.3%)	28 (27.2%)	1 (50%)	1 (100%)	13 (30.2%)	2 (11.8%)
41-50	44 (22.9%)	7 (26.9%)	26 (25.2%)			7 (16.3%)	4 (23.5%)
> 50	21 (10.9%)	3 (11.5%)	14 (13.6%)			2 (4.7%)	2 (11.8%)

[†] Abbreviations: HBsAg+/-, Hepatitis B surface antigen positive/negative; HBsAb+/-, Hepatitis B surface antibody positive/negative; HBcAb+/-, Hepatitis B core antibody positive/negative

Table 3: Prevalence of HBeAg and HBeAb among apparently healthy participants in Ibadan and Ogbomosh, Oyo State, Nigeria

Variable	HBsAg+	HBsAb+	Isolated HBcAb+
HBeAg+	13	0	0
HBeAg-	31	28	103
Total	44	28	103
HBeAb+	27	7	10
HBeAb-	17	21	93
Total	44	28	103

[†] Abbreviations: Isolated HBcAb, Hepatitis B core antibody positive as the only marker of infection; HBeAg+/-, Hepatitis B e antigen positive/negative; HBeAb+/-, Hepatitis B e antibody positive/negative

3.3. Risk factors associated with HBV positivity

One hundred and forty-seven (76.6%) individuals were presently seropositive for HBV infection without the neutralizing surface antibodies (HBsAb), this consists of 44 for current infection (HBsAg+) and 103 for past infection (isolated HBcAb+) (Table 3). The sex distribution of prevalence of 96 and 51 for female and male, respectively, was not statistically significant, while the seropositive individuals were found in all age groups. The association of other risk factors with infection was determined. In multivariate analysis, scarification ($P = .01$) and sharing of sharp instruments/tools ($P = .01$) were significantly and independently associated with Hepatitis B infection in the study (Tables 4 & 5). However, blood transfusion, indiscriminate injection from unqualified healthcare workers, previous surgery, multiple sex partners, and injection drug use were not significantly associated with HBsAg and HBcAb seropositivity.

Table 4: Multivariate logistic regression analysis of risk factors potentially associated with HBsAg positivity among apparently healthy participants in Ibadan and Ogbomosho, Oyo State, Nigeria

Variable	Odds Ratio (OR)	95% CI for OR		P-value
		Lower bound	Upper bound	
Age group				.40
Sex	1.118	.234	5.350	.89
Scarification	.081	.011	.589	.01*
Blood transfusion	2.428	.192	30.769	.49
Tattooing	42384978.86	.000		1.00
Surgery	1.442	.103	20.162	.79
Injection from quacks	1.921	.356	10.369	.45
Injection drug use	198976893.27	.000		1.00
Multiple sex partners	2.133	.331	13.762	.43
Sharing of sharp instruments/tools	1.551	.344	6.995	.57
Hepatitis B immunization	.407	.062	2.661	.35

* Significant risk factors; $P < 0.05$

Table 5: Multivariate logistic regression analysis of risk factors potentially associated with isolated HBcAb positivity among apparently healthy participants in Ibadan and Ogbomosho, Oyo State, Nigeria

Variable	Odds Ratio (OR)	95% CI for OR		P-value
		Lower bound	Upper bound	
Age group				.59
Sex	.597	.137	2.602	.49
Scarification	.278	.072	1.075	.06
Blood transfusion	.174	.018	1.714	.13
Tattooing	2.298	.274	19.239	.44
Surgery	.945	.146	6.111	.95
Injection from quacks	.561	.147	2.143	.40
Injection drug use	.000	.000		1.00
Multiple sex partners	.606	.105	3.490	.58
Sharing of sharp instruments/tools	24.051	2.420	239.078	.01*
Hepatitis B immunization	2.769	.569	13.471	.21

4. Discussion

The pilot study investigated the prevalence of HBV markers among apparently healthy individuals in two largest cities of Oyo state (Ibadan and Ogbomosho), with a view to provide

223 potential evidence for viral factors in the unabated transmission of HBV in spite of over 10
224 years of neonatal immunization. This is necessary to generate data to appropriately target
225 prevention/control measure for individuals born before the nationwide implementation of
226 hepatitis B vaccine in the EPI in Nigeria in 2004.

227 An overall prevalence of 22.9% (44/192) was observed for active hepatitis B infection among
228 participants. The seroprevalence of 22.9% is consistent with previous reports from Nigeria
229 [4-7]. The reported prevalence ranges from 10.3% - 44.7%, depending on the sampling
230 population. However, it was found to be much lower than the prevalence's among people
231 living with HIV in Gombe (26.5%), chronic liver disease patients at a Nigerian Teaching
232 Hospital (40%), primary school children in a rural community in Borno state (44.7% [4-5, 7].
233 The reason for this large difference might be because the surveys involved high risk groups.
234 Although the number of male participants was lower than that of the females (61 vs. 131),
235 the HBsAg seropositivity was higher among them (54.5% vs. 45.5%). Similar reports
236 independent of the prevailing risk factors and degree of endemicity have been documented
237 in populations randomly sampled for HBsAg seroprevalence [7, 13-14]. The higher
238 prevalence among the males has been attributed to the fast clearance of HBsAg in women
239 [15]. Hepatitis B surface antigen carriage was found to increase with age and by 40 years;
240 consequently, 79% have been infected. This according to El Beltagy *et al* (2008) may have
241 been due to potential exposure over a long period of time, the non-immunization status of
242 the older population as well as the lack of information on HBV infection and transmission in
243 the past decades [16].

244 A lifetime exposure of 90% (HBcAb-Total) for HBV positivity due to past or present exposure
245 was observed. This is in agreement with Alter (2002) that there could be 70-90% serological
246 evidence of HBV exposure among populace in the highly endemic regions of South East
247 Asia, sub-Saharan African and the Amazon Basin [2]. Similar studies reported 43.9% and
248 72.4% in China and Uganda respectively [17-18]. The endemicity of hepatitis B was revealed
249 in the exposure pattern. This increase with age and by 50 years, 86.4% of the participants
250 was infected.

251 Reports from several studies have implicated several risk factors in the transmission and
252 acquisition of HBV. These include low educational level, used needles and syringes, family
253 history of hepatitis B, scarification, dental procedure, sexually transmitted infections, sharing
254 of multiple sex partners and lack of immunization with HB vaccine [7, 16, 19-20]. However,
255 tattooing, percutaneous injection drug use and high-risk sexual activity have accounted for
256 most cases of newly acquired hepatitis B in the developed countries [21-23]. In the present
257 study, scarification ($P = .01$) and sharing of sharp instruments/tools ($P = .01$) were
258 significantly associated with the prevalence of HBsAg and HBcAb respectively. Scarification
259 has been an age long cultural practice among various tribes in Africa for defining identity,
260 beauty, strength, and rites of passage. This is usually done by traditional practitioners using
261 blades and knives soaked in cleansing liquids. However, this practice has been identified as
262 a significant factor in the spread of HBV in the region [7, 24-25]. Sharing of sharp
263 instruments and tools was found to be independently associated with the prevalence of
264 HBcAb in this study. These include grooming items (razor, toothbrushes, and shaving/hair
265 clippers) as well as tools for daily work tasks; they can serve as effective inanimate vehicles
266 especially during percutaneous exposure to source positive for HBeAg. Instrument and tool
267 sharing is a common practice within households and work places and has been documented
268 as a significant source of HBV transmission [24, 26].

269 Fifty-four percent (103/192) of the participants had isolated HBcAb. The prevalence of 54%
270 is higher than previous report from Nigeria [27-28]. This may not be unconnected with the
271 fact that the present study included a wider population range compared to the cohorts of
272 blood donors and HIV patients on anti-retroviral therapy (ART) in previous studies. The
273 presence of isolated HBcAb has been an issue of great concern with regard to HBV
274 transmission. Often it represents a remote resolved infection, a low-level chronic infection, or
275 the presence of a "window phase" between the disappearance of HBsAg and the appearance

of HBsAb [29]. The potential for active hepatitis B infection in isolated HBcAb was demonstrated by HBV transmission from blood and organ donors who had isolated HBcAb [9-12]. Several studies from India, a developing country endemic for HBV infection documented HBV DNA detection (12.4% - 27.2%) in persons with isolated anti-HBc [30-32]. This poses a great risk to recipients of blood products and organs from anti-HBc individuals. Also these HBsAg seronegative DNA carriers are at risk for hepatitis B reactivation, following immunosuppressive therapy. In light of the above, therefore, Anti-core antibody screening should be implemented in the screening guideline for blood/organ donation as well as hepatitis B diagnosis in Nigeria. A decline in new infection of HBV occurred in several endemic countries following the introduction of anti-core screening [29, 33-34] while nucleic acid testing (NAT) was recently implemented in low prevalence countries (Ireland, 2002; Germany, 2002; Canada, 2005). According to Pereira (2003) and Jackson *et al* (2003), this had a small health benefit in the European Union and the USA at a very high cost relative to other blood safety measure. However it has been predicted that there would be a greater benefit in countries with high hepatitis B prevalence [35-36]. Therefore participants with isolated HBcAb positive in this study shall be investigated further using HBV vaccination and HBV DNA testing to rule out chronic infection. However those found infected would be referred for appropriate treatment and follow-up.

Although only 15.6% of the participants were vaccinated, vaccination appears not to be a significant factor in disease prevention ($P>0.05$). The result from this study showed that only 6.7% (2/30) of the vaccinees had protective immunity. This is highly suggestive of incomplete vaccination, although the study failed to include the number of hepatitis B vaccine doses taken in the data collection. Also this may not be unconnected with the fact that only small percentage of the participants was vaccinated. The incidence of hepatitis B in the developed countries has been reduced greatly by active infant vaccination, while a more comprehensive and established infrastructure for vaccine delivery to adolescents and adults has been implemented with considerable success in the USA [37-38]. Hence, the need for increased public awareness campaign for vaccination and possibly vaccine availability free of charge for adults in Nigeria. This as a suggested strategy for combating HBV spread caters for the adult population as they enter into the ages of greatest incidence of infection.

5. CONCLUSION

The study highlights potential risks associated with the current diagnostic guideline for hepatitis B status and advocates the need for adult population vaccination. Vaccination is the most effective strategy to halt HBV infection and until aggressive vaccination of the adults is embarked upon, the risk for hepatitis B infection and associated chronic liver diseases will continue unabated for many years to come.

LIMITATIONS OF THE STUDY

This study has some limitations. First, the self-reporting nature of risk factors may be subject to recall and social desirability bias. Second, the sample size of 384 was halved due to the financial implication of the ELISA kits used for the analysis.

ETHICAL APPROVAL

322 The study was approved by the University of Ibadan/University College Hospital ethics
323 committee and its participants provided written or oral informed consent.

324

325 REFERENCES

326

- 327 1. World Health Organization. Hepatitis B: Emergencies preparedness, response.
328 2015a. Accessed 8 July 2015. Available:
329 <http://www.who.int/csr/disease/hepatitis/whodscsrlyo20022/en/index1.html>.
- 330 2. Alter M. Epidemiology of hepatitis B in Europe and worldwide. *J Hepatol*.
331 2003;39:S64–9.
- 332 3. World Health Organization. Hepatitis B Fact sheet N 204. 2015b. Accessed 12 July
333 2015. Available: <http://www.who.int/mediacentre/factsheets/fs204/en/>.
- 334 4. Mustapha SK, Jibrin YB. The Prevalence of hepatitis B surface antigenemia in
335 patients with Human Immunodeficiency Virus infection in Gombe, Nigeria. *Ann Afr*
336 *Med*. 2004;4:10-12.
- 337 5. Bukbuk DN, Bassi AP, Mangoro ZM. Sero-prevalence of hepatitis B surface antigen
338 among primary school pupils in rural Hawal valley, Borno State, Nigeria. *J*
339 *Community Med Primary Health Care*. 2005;17(1):20-3.
- 340 6. Onuzulike N, Ogueri EO. Sero-prevalence of hepatitis B surface antigen in pregnant
341 women in Owerri, Imo State of Nigeria. *Res J Bio Sci*. 2007;2(2):178-82.
- 342 7. Omuemu CE, Ndububa DA, Nnabuchi CV. Prevalence of hepatitis B surface antigen
343 and anti-hepatitis C antibodies in chronic liver disease patients in a Nigerian
344 Teaching Hospital. *J Med Res Practice*. 2012;1(2). Accessed 14 July 2015.
345 Available: <http://www.journalmanagers.com/index.php/jmrp/article/view/19>.
- 346 8. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for
347 decades after patients' recovery from acute viral hepatitis despite active
348 maintenance of a cytotoxic T-lymphocyte response. *Nat Med*. 1996;2: 1104-08.
- 349 9. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of
350 transplantation-associated de novo hepatitis B infection in the liver transplant
351 recipient. *Liver Transpl Surg*. 1997;3:105-11.
- 352 10. Dickson RE, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH *et al*.
353 Transmission of hepatitis B by transplantation of livers from donors positive for
354 antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive
355 Kidney Diseases Liver Transplantation database. *Gastroenterology*. 1997;113:1668-
356 74.
- 357 11. Gow PJ, Mutimer DJ. De novo hepatitis B infection acquired during liver
358 transplantation. *QJM*. 2001;94:271-75.
- 359 12. isolated hepatitis B core antibody in blood donors from Sao Paulo. *Rev Inst Med*
360 *Trop Sao Paulo*. 2001;43:203-08.
- 361 13. Amidu N, Alhassan A, Obirikorang C, Feglo P, Majeed SF, Timmy-Donkoh E. *et al*.
362 Sero-prevalence of hepatitis B surface antigen in three densely populated
363 communities in Kumasi, Ghana. *J Med Biomed Sci*. 2012;1(2):59-65.
- 364 14. Andoulo FA, Tagni-Sartre M, Dominique NN, Djapa R, Ndam ECN. Prevalence of
365 hepatitis B surface antigen in a population of workers in Cameroon. *Open Journal of*
366 *Gastroenterology*. 2013;3:323-27.
- 367 15. Sharma SK, Saini N, Chwla Y..(2005) Hepatitis B virus: inactive carriers. *Viol J*.
368 2005;2:82. doi:10.1186/1743-422X-2-82.
- 369 16. EL Beltagy KE, Al Balawi IA, Almuneef M, Memish ZA. Prevalence of hepatitis B
370 virus markers among blood donors in a tertiary hospital in Tabuk, NorthWestern,
371 Saudi Arabia. *Int J Infet Dis*. 2008;12(5):495-99.

17. Ochola E, Ocamo P, Orach CG, Nankinga ZK, Kalyango JU, McFarland W. *et al.* (2013) High burden of hepatitis B infection in Northern Uganda: results of a population-based survey. *BMC Public Health*. 2013;13:727. doi: 10.1186/1471-2458-13-727
18. Ji Z, Wang T, Shao Z, Huang D, Wang A, Guo Z. *et al.* A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. *PLoS ONE*. 2014;9(5):e97474. doi:10.1371/journal.pone.0097474.
19. Awadalla HI, Ragab MH, Osman MA, Nassar NA. Risk factors of viral hepatitis B among Egyptian blood donors. *Br J Med Med Res*. 2011;1(1):7-13.
20. Mboto CI, Edet EJ. Prevalence and risk factors of hepatitis B virus infection among students in University of Uyo. *Int J Modern Bio Med*. 2012;2(2):101-11.
21. Spada E, Mele A, Ciccozzi M, Tosti ME, Bianco E, Szklo A. *et al.* Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. *Digest Liver Dis*. 2001;33:778-84.
22. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K *et al.* Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. *J Infect Dis*. 2002;185(6):713-9.
23. Boullos D, Goedhuis NJ, Wu J, Baptiste B, Poliquin D, Furseth J *et al.* Enhanced surveillance for acute and likely acute hepatitis B in Canada: 1999 to 2002. *Can J Infect Dis Med Microbiol*. 2005;16(5):275-81.
24. Nwokediuko S. (2009) Risk Factors for hepatitis B virus transmission in Nigerians: a case-control study. *The Internet Journal of Gastroenterology*. 2009;10(1). Accessed 14 July 2015. Available: ispub.com/IJGE/10/1/11182.
25. Ben-Alaya-Bouafif N, Bahri O, Chlif S, Bettaieb J, Toumi A, Bel Haj HN. *et al.* Heterogeneity of hepatitis B transmission in Tunisia: risk factors for infection and chronic carriage before the introduction of a universal vaccine program. *Vaccine*. 2010;28(19):3301-07.
26. Nwokediuko S, Ijoma U. Relatively high seroprevalence of hepatitis B surface antigen in female civil servants in Enugu State of Nigeria. *EuroAsian journal of Hepato-Gastroenterology*. 2011;1(1):19-22.
27. Jeremiah ZA, Idris H, Ajayi BB, Ezimah AC, Malah MB, Baba MM. Isolated anti-HBc-IgM antibody among blood donors in the semi- arid region of Nigeria. *Human Antibodies*. 2011;20(3-4):7-82. doi: 10.3233/HAB-2011-0242.
28. Oluyinka OO, Atiba A, Oluremi AS, Ojo J, Odewale G. Prevalence of anti-HBc in HIV patients on ART in Ekiti, Nigeria. *International Journal of Tropical Disease and Health*. 2015;8(2):75-8.
29. Busch MD. Prevention of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. *Vox Sang*. 1998;74(2):147-54
30. Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti-Hbc titer and PCR-amplified HBV DNA. *Transfusion*. 2003;43:1442-48.
31. Banerjee A, Chandra PK, Datta S, Biswas A, Bhattacharya P, Chakraborty S. *et al.* Frequency and significance of hepatitis B virus surface gene variant circulating among 'antiHBc only' individuals in Eastern India. *J Clin Virol*. 2007;40:312-17.
32. Asim M, Ali R, Khan LA, Husain SA, Singla R, Kar P. Significance of anti-HBc screening of blood donors and its association with occult hepatitis B virus infection: implications for blood transfusion. *Indian J Med Res*. 2010;132:312-17.
33. Japanese Red Cross non-A, non-B Hepatitis Research Group. Effect of screening for hepatitis C virus and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. *Lancet*. 1991;338:1040-41.

- 423 34. Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR. *et al.*
424 Donor screening for antibody to hepatitis B core antigen and hepatitis B virus
425 infection in transfusion recipients. *Transfusion*. 1995;35(1):5-12.
426 35. Pereira A. Health and economic impact of post-transfusion hepatitis B and cost-
427 effectiveness analysis of expanded HBV testing protocols of blood donors: a study
428 focused on the European Union. *Transfusion*. 2003;43:192-201.
429 36. Jackson BR, Busch MP, Stramer S, AuBuchon JP. The cost-effectiveness of NAT
430 for HIV, HCV and HBV in whole blood donations. *Transfusion*. 2003;43:721-29.
431 37. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. *Int J*
432 *Med Sci*. 2005;2(1): 20-23.
433 38. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L. *et al.* 2006) A
434 comprehensive immunization strategy to eliminate transmission of hepatitis B virus
435 infection in the United States. *MMWR*. 2006;55(RR16):1-25.
436